OrbiMed, Novo Holdings and Blue Owl Capital led a $200m Series A round in Windward Bio.

OrbiMed, an investment firm, Novo Holdings, a holding and investment company, and Blue Owl Capital, an asset manager, led a $200m Series A round in Windward Bio, a clinical-stage, drug development company, with participation from SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. “By leading the investment in Windward Bio, we see the opportunity to leverage a highly successful team to create a biopharmaceutical company that can bring best-in-class therapeutics to people living with asthma, COPD, and other immunological conditions,” David Bonita, OrbiMed General Partner.